These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 11942772

  • 21. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin.
    Nestel P, Simons L, Barter P, Clifton P, Colquhoun D, Hamilton-Craig I, Sikaris K, Sullivan D.
    Atherosclerosis; 1997 Mar 21; 129(2):231-9. PubMed ID: 9105566
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG.
    Am J Cardiol; 2001 Jan 01; 87(1):44-8. PubMed ID: 11137832
    [Abstract] [Full Text] [Related]

  • 24. Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.
    Sommariva D, Bonfiglioli D, Pogliaghi I, Ottomano C, Fasoli A.
    Eur J Clin Pharmacol; 1984 Jan 01; 26(6):741-4. PubMed ID: 6489413
    [Abstract] [Full Text] [Related]

  • 25. Combination drug therapy for familial combined hyperlipidemia.
    East C, Bilheimer DW, Grundy SM.
    Ann Intern Med; 1988 Jul 01; 109(1):25-32. PubMed ID: 3288029
    [Abstract] [Full Text] [Related]

  • 26. The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.
    Paragh G, Seres I, Harangi M, Balogh Z, Illyés L, Boda J, Szilvássy Z, Kovács P.
    Diabetes Metab; 2003 Dec 01; 29(6):613-8. PubMed ID: 14707891
    [Abstract] [Full Text] [Related]

  • 27. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia.
    Civeira F, Cenarro A, Ferrando J, Puzo J, Garcia-Otín AL, Mozas P, Pocoví M.
    Am Heart J; 1999 Jul 01; 138(1 Pt 1):156-62. PubMed ID: 10385780
    [Abstract] [Full Text] [Related]

  • 28. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ, Lamon-Fava S, Cole T, Sprecher DL, Cilla DD, Balagtas CC, Rowan JP, Black DM.
    Atherosclerosis; 1996 Nov 15; 127(1):113-22. PubMed ID: 9006811
    [Abstract] [Full Text] [Related]

  • 29. Long-term effects of fenofibrate on serum lipids and on lipoprotein cholesterol in type II hyperlipoproteinemic patients.
    Sommariva D, Bonfiglioli D, Pogliaghi I, Cabrini E, Fasoli A.
    Pharmacol Res Commun; 1984 Aug 15; 16(8):809-20. PubMed ID: 6593751
    [Abstract] [Full Text] [Related]

  • 30. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
    Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J.
    N Engl J Med; 1999 Aug 05; 341(6):410-8. PubMed ID: 10438259
    [Abstract] [Full Text] [Related]

  • 31. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
    Bredie SJ, de Bruin TW, Demacker PN, Kastelein JJ, Stalenhoef AF.
    Am J Cardiol; 1995 Feb 15; 75(5):348-53. PubMed ID: 7856526
    [Abstract] [Full Text] [Related]

  • 32. A comparison of different formulations and dosage administrations of gemfibrozil.
    Kovanen PT, Koskinen P, Manninen V.
    Am J Cardiol; 1986 May 30; 57(14):31G-34G. PubMed ID: 3459351
    [Abstract] [Full Text] [Related]

  • 33. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study.
    Tikkanen MJ, Laakso M, Ilmonen M, Helve E, Kaarsalo E, Kilkki E, Saltevo J.
    Diabetes Care; 1998 Apr 30; 21(4):477-81. PubMed ID: 9571327
    [Abstract] [Full Text] [Related]

  • 34. Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels.
    Sharpe M, Ormrod D, Jarvis B.
    Am J Cardiovasc Drugs; 2002 Apr 30; 2(2):125-32; discussion 133-4. PubMed ID: 14727988
    [Abstract] [Full Text] [Related]

  • 35. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
    Okopien B, Cwalina L, Lebek M, Kowalski J, Zielinski M, Wisniewska-Wanat M, Kalina Z, Herman ZS.
    Int J Clin Pharmacol Ther; 2001 Dec 30; 39(12):551-7. PubMed ID: 11770837
    [Abstract] [Full Text] [Related]

  • 36. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.
    Diabetes; 2003 Mar 30; 52(3):803-11. PubMed ID: 12606523
    [Abstract] [Full Text] [Related]

  • 37. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM.
    Am J Cardiol; 2003 Apr 15; 91(8):956-60. PubMed ID: 12686335
    [Abstract] [Full Text] [Related]

  • 38. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study.
    Manninen V, Huttunen JK, Heinonen OP, Tenkanen L, Frick MH.
    Am J Cardiol; 1989 May 02; 63(16):42H-47H. PubMed ID: 2650524
    [Abstract] [Full Text] [Related]

  • 39. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
    Farnier M, Ducobu J, Bryniarski L.
    Curr Med Res Opin; 2011 Nov 02; 27(11):2165-73. PubMed ID: 21973199
    [Abstract] [Full Text] [Related]

  • 40. A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus.
    Schweitzer M, Tessier D, Vlahos WD, Leiter L, Collet JP, McQueen MJ, Harvey L, Alaupovic P.
    Atherosclerosis; 2002 May 02; 162(1):201-10. PubMed ID: 11947915
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.